Study guide
15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
Key Takeaways Explain This Topic AI
Project MATCH randomized 1,726 participants and found cognitive behavioral therapy, motivational enhancement therapy and twelve-step facilitation produced clinically equivalent drinking reductions.
Twelve-step facilitation is a manualized clinical intervention delivered by a professional and is distinct from Alcoholics Anonymous itself, which is a free mutual-help fellowship.
Cochrane evidence indicates manualized twelve-step facilitation produces higher continuous abstinence rates than other well-established treatments, largely by increasing mutual-help participation.
Marlatt's relapse-prevention model distinguishes a lapse from a relapse and targets the abstinence violation effect, which converts a single drink into a full return to use.
Recovery capital — personal, social, community and cultural resources — predicts sustained remission better than substance-use severity alone.
Last updated: September 2026
15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
Quick Answer: Project MATCH (N = 1,726) showed CBT, motivational enhancement therapy and twelve-step facilitation produce equivalent outcomes , refuting the matching hypothesis. Twelve-step facilitation (TSF) is a manualized professional intervention that links patients to mutual help; it is not the same thing as Alcoholics Anonymous , which is a free, autonomous fellowship. Marlatt's relapse-prevention model separates a lapse (a single episode) from a relapse (return to prior pattern) and targets the abstinence violation effect . Recovery capital predicts long-term remission.
1. The Equivalence Finding and What It Means Clinically
Project MATCH tested whether patient characteristics could be matched to specific therapies. Of dozens of hypothesized interactions, essentially one reached significance. All three therapies produced large, durable reductions in drinking sustained at 1- and 3-year follow-up.
The clinical implication is not "therapy doesn't matter." It is that fit, access and engagement matter more than modality . The exam-relevant consequence: when a stem asks which behavioral therapy to recommend, the best answer is usually the one the patient will actually attend, not the one with the most impressive name.
2. Mutual-Help Options
Program Orientation Notes for referral
Alcoholics Anonymous (AA) Twelve-step, spiritual but not religious, abstinence-based Largest network; free; sponsor relationship is the active ingredient for many
Narcotics Anonymous (NA) Twelve-step, all substances Some groups historically unwelcoming to members on methadone or buprenorphine — screen local meeting culture before referring a patient on MOUD
SMART Recovery Cognitive behavioral, motivational, science-based; four-point program No sponsor or higher power; accepts medication; online meetings widely available
Refuge Recovery / Recovery Dharma Buddhist-informed mindfulness Good fit for patients averse to a higher-power framework
Women for Sobriety Cognitive, women-specific, emphasizes emotional growth Alternative for women uncomfortable in mixed-gender settings
- LifeRing Secular Recovery Secular, abstinence-based, self-directed No steps, no sponsor
- Medication-friendly meetings Varies Increasingly labeled explicitly; worth maintaining a local list
Critical APRN counseling point: a patient on buprenorphine or methadone who is told at a meeting that they are "not really clean" is at elevated risk of stopping medication. Prepare the patient for that possibility, give them language to respond, and know which local meetings are explicitly medication-supportive.
TSF versus AA on the exam
Twelve-step facilitation is a structured, time-limited, professionally delivered treatment whose explicit goal is to engage the patient in a twelve-step fellowship. Cochrane review evidence indicates manualized TSF produces higher rates of continuous abstinence than comparison treatments, with most of the effect mediated by increased mutual-help attendance. Referring a patient to AA is not the same as delivering TSF.
3. The Relapse-Prevention Model
Identify high-risk situations. The classic triad is negative emotional states (the most common single precipitant), interpersonal conflict , and social pressure .
Build coping responses. Rehearse specific behavioral scripts, not intentions. "I will leave at 8 and I have already told my brother he is my ride" beats "I'll be careful."
Address outcome expectancies. Patients remember the anticipated relief, not the consequences. Decisional balance work makes the full sequence visible.
Defuse the abstinence violation effect (AVE). After one drink, an all-or-nothing attributional style — "I've blown it, I'm a failure, I may as well finish the bottle" — converts a lapse into a relapse. Teaching patients in advance that a lapse is a data point rather than a verdict measurably shortens episodes.
Watch seemingly irrelevant decisions. The chain that ends in use often starts with an apparently trivial choice, such as taking the route that passes the old bar.
4. Recovery Capital
Domain Examples APRN intervention
Personal Physical health, self-efficacy, coping skills, hope Treat co-occurring conditions; celebrate concrete gains
Social Family, sober friends, sponsor, employer support Family education; mutual-help linkage; CRAFT for concerned significant others
Community Housing, transportation, recovery housing, employment programs, mutual-help density Case management and warm handoffs
Cultural Faith community, cultural identity, language-concordant services Match referrals to identity, not just diagnosis
Recovery capital predicts sustained remission better than baseline severity does, which reframes the plan: adding housing and a job is not "social work instead of treatment," it is treatment.
5. Recovery Management Rather Than Episodic Care
Alcohol use disorder behaves like other chronic conditions, with remission and recurrence. Recovery management checkups — scheduled, proactive contacts at 3, 6 and 12 months regardless of status — detect recurrence earlier and re-engage patients faster than waiting for the patient to call. Telling a patient at discharge "call us if you relapse" places the burden on the person whose executive function is most impaired at the moment of highest craving.